Literature DB >> 15003201

Oestrogen receptor beta: what it means for patients with breast cancer.

Valerie Speirs1, Pauline J Carder, Sally Lane, David Dodwell, Mark R J Lansdown, Andrew M Hanby.   

Abstract

Oestrogen receptor (ER) alpha is a well established prognostic marker in breast cancer, and all patients who are ER alpha positive receive tamoxifen as adjuvant endocrine therapy. Although ER alpha predicts a favourable disease outcome, the usefulness of ER beta as a clinical prognostic marker remains to be defined. Here, we outline the history of both ERs and discuss the implications ER beta has to patients with breast cancer.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15003201     DOI： 10.1016/S1470-2045(04)01413-5

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


  21 in total

1.  Genome-wide dynamics of chromatin binding of estrogen receptors alpha and beta: mutual restriction and competitive site selection.

Authors:  Tze Howe Charn; Edison Tak-Bun Liu; Edmund C Chang; Yew Kok Lee; John A Katzenellenbogen; Benita S Katzenellenbogen
Journal:  Mol Endocrinol       Date:  2009-11-06

2.  Synthesis and biological evaluation of two agents for imaging estrogen receptor β by positron emission tomography: challenges in PET imaging of a low abundance target.

Authors:  Jae Hak Lee; Olaf Peters; Lutz Lehmann; Carmen S Dence; Terry L Sharp; Kathryn E Carlson; Dong Zhou; M Jeyakumar; Michael J Welch; John A Katzenellenbogen
Journal:  Nucl Med Biol       Date:  2012-06-30       Impact factor: 2.408

3.  Pro-apoptotic and anti-proliferative effects of mitofusin-2 via PI3K/Akt signaling in breast cancer cells.

Authors:  L I Ma; Yuan Chang; Long Yu; Wenbo He; Yueping Liu
Journal:  Oncol Lett       Date:  2015-09-25       Impact factor: 2.967

4.  Mechanisms enforcing the estrogen receptor β selectivity of botanical estrogens.

Authors:  Yan Jiang; Ping Gong; Zeynep Madak-Erdogan; Teresa Martin; Muthu Jeyakumar; Kathryn Carlson; Ikhlas Khan; Troy J Smillie; Amar G Chittiboyina; Sateesh C K Rotte; William G Helferich; John A Katzenellenbogen; Benita S Katzenellenbogen
Journal:  FASEB J       Date:  2013-07-23       Impact factor: 5.191

5.  TARGETING THE GENOTOXIC EFFECTS OF ESTROGENS.

Authors:  Monica M Montano; Nirmala Krishnamurthy; Smitha Sripathy
Journal:  Drug Discov Today Dis Mech       Date:  2012

Review 6.  Evaluation of the potential antidepressant effects of soybean isoflavones.

Authors:  Mark Messina; Carey Gleason
Journal:  Menopause       Date:  2016-12       Impact factor: 2.953

7.  Deregulation of estrogen receptor coactivator proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor in human endometrial tumors.

Authors:  Ratna K Vadlamudi; Seetharaman Balasenthil; Russell R Broaddus; Jan-Ake Gustafsson; Rakesh Kumar
Journal:  J Clin Endocrinol Metab       Date:  2004-12       Impact factor: 5.958

8.  Estrogen receptor beta2 and beta5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion.

Authors:  Yuet-Kin Leung; Hung-Ming Lam; Shulin Wu; Dan Song; Linda Levin; Liang Cheng; Chin-Lee Wu; Shuk-Mei Ho
Journal:  Endocr Relat Cancer       Date:  2010-06-25       Impact factor: 5.678

9.  Support of a bi-faceted role of estrogen receptor β (ERβ) in ERα-positive breast cancer cells.

Authors:  Philip Jonsson; Anne Katchy; Cecilia Williams
Journal:  Endocr Relat Cancer       Date:  2014-01-30       Impact factor: 5.678

10.  Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation.

Authors:  Maria G Raso; Carmen Behrens; Matthew H Herynk; Suyu Liu; Ludmila Prudkin; Natalie C Ozburn; Denise M Woods; Ximing Tang; Reza J Mehran; Cesar Moran; J Jack Lee; Ignacio I Wistuba
Journal:  Clin Cancer Res       Date:  2009-08-25       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.